InVivo Therapeutics Announces St. Michael’s Hospital As New Canadian Site For INSPIRE Study

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that the St. Michael’s Hospital has been added as a Canadian clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The St. Michael’s Hospital is InVivo’s second site in Toronto and sees over 70,000 emergency visits annually.

“My research focuses on engineering applications to neurosurgical procedures with the goal of improving safety and outcome for patients. The INSPIRE study holds much promise for this large unmet medical need and I look forward to participating”

“My research focuses on engineering applications to neurosurgical procedures with the goal of improving safety and outcome for patients. The INSPIRE study holds much promise for this large unmet medical need and I look forward to participating,” said Howard Ginsberg, M.D., Ph.D., Assistant Professor in the Department of Surgery and the Institute of Biomaterials and Biomedical Engineering, and Principal Investigator at the study site.

Mark Perrin, InVivo’s CEO and Chairman, said, “We are pleased to welcome Dr. Ginsberg and his team at the St. Michael’s Hospital to the INSPIRE study. The Toronto metropolitan area has the largest population in Canada, and St. Michael’s Hospital is one of two adult level I trauma centers to service the area.”

There are now 28 clinical sites participating in the clinical study:

• Allegheny General Hospital, Pittsburgh, PA
• Banner University Medical Center, Tucson, AZ
• Barnes-Jewish Hospital at Washington University Medical Center, St. Louis, MO
• Barrow Neurological Institute – St. Joseph’s Hospital and Medical Center, Phoenix, AZ
• Ben Taub Hospital/Baylor College of Medicine, Houston, TX
• Beth Israel Deaconess Medical Center, Boston, MA
• Carolina Neurosurgery and Spine Associates/Carolinas Rehabilitation, Charlotte, NC
• Cooper Neurological Institute, Camden, NJ
• Foothills Medical Centre, Calgary, Alberta, Canada
• Goodman Campbell Brain and Spine/Indiana University Health Neuroscience Center, Indianapolis, IN
• Hospital of the University of Pennsylvania, Philadelphia, PA
• Keck Hospital of University of Southern California, Los Angeles, CA
• Medical College of Wisconsin/Froedtert Hospital, Milwaukee, WI
• Mount Sinai Hospital, New York, NY
• Northwestern Medicine, Chicago, IL
• Oregon Health & Science University, Portland, OR
• Rutgers New Jersey Medical School, Newark, NJ
• St. Michael’s Hospital, Toronto, Ontario, Canada
• Thomas Jefferson University Hospital, Philadelphia, PA
• Toronto Western Hospital, Toronto, ON, Canada
• University of California, Davis Medical Center, Sacramento, CA
• University of California, San Diego Medical Center, San Diego, CA
• University of Iowa Hospitals and Clinics, Iowa City, IA
• University of Kansas Medical Center, Kansas City, KS
• University of Louisville Hospital, Louisville, KY
• University of Pittsburgh Medical Center Presbyterian, Pittsburgh, PA
• University of Virginia Health System, Charlottesville, VA
• Vidant Medical Center, Greenville, NC

For more information, please visit the company’s ClinicalTrials.gov registration site: http://clinicaltrials.gov/ct2/show/study/NCT02138110

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.